Bibliografía del artículo
1. Blokhina O, Virolainen E, Fagerstedt KV. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann Bot (Lond) 91:179-94, 2003.
2. Scandalios JG. Oxidative stress: molecular perception and trans- duction of signals triggering antioxidant gene defensas. Braz J Med Res 38:995-1014, 2005.
3. Young IS, Woodside JV. Antioxidants in health and disease. J Clin Pathol 54:176-86, 2001.
4. Halliwell B, Gutteridge JMC, eds. Antioxidant defenses. In Free Radicals in Biology and Medicine , 3rd ed. New York: Oxford University Press; 1998.
5. Willcox J, Ash S, Catignani G. Antioxidants and prevention of chronic disease. Crit Rev Food Sci Nutr 44:275-95, 2004.
6. Tribble DL, Frank E. Dietary antioxidants, cancer and atherosclerotic heart disease. West J Med 161:605-12, 1994.
7. Ortiz A, Vargas R, Muñóz G. Incidencia y mortalidad del cáncer en Costa Rica. Costa Rica: Kamelot Comunicació n y Arte; 2005.
8. Stocker R, Keaney J. Role of oxidative modiffications in atherosclerosis. Physiol Rev 84:1381-478, 2004.
9. Heinecke J. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141:1-15, 1998.
10. Salonen T, Yla-Herttulal S, Yamamoto R. Autoantibodies against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-7, 1992.
11. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. ACJN 53:326-34S, 1991.
12. Stampfer MJ, Hennekens CH, Manson J, Colditz G, Rosner B, Willett W. Vitamin E consumption and risk of coronary disease in women. N Engl J Med 328:1444-9, 1993.
13. Stephens NG, Parsons A, Schoeld PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 347:781-6, 1996.
14. Yusuf S. Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 354:1917-18, 2000.
15. Ebell MH. Efficacy of antioxidants in GI cancer prevention. Am Fam Physician 71:465-6, 2005.
16. Salaganik RL. The beneffits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 20(Suppl):464-75S, 2001.
17. Lamson DW, Brignall MS. Antioxidants and cancer. 3. Quercetin. Altern Med Rev 5:304-29, 2000.
18. Christen Y. Oxidative stress in Alzheimer' s disease. Am J Clin Nutr 71:621-9S, 2000.
19. Smith MA, Perry G, Richery PL. Oxidative damage in Alzheimer' s disease. Nature 382:120-1, 1996.
20. Age-related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age related cataract and vision loss: AREDS report Nº 9. Arch Ophthalmol 119:1439-52, 2001.
21. Ehret A, Westendorp MO, Herr I, et al. Resistance of chimpanzee T cells to human virus type 1 Tat-enhanced oxidative stress and apoptosis. J Virol 70:6502-7, 1996.
22. Strehlow K, Rotter S, Wassmann S, et al. Modulation of antioxidant lipid expression and function by estrogen . Circ Res 93:170-7, 2003.
23. Unfer T, Conterato M, da Silva J, Duarte M, Emanuelli T. Inffluence of hormonal replacement therapy on blood antioxidant enzymes in menopausal women. Clin Chem Acta 369:73-7, 2006.
24. Signorelli S, Neri S, Sciacchitano S, DiPino L, Costa M, Marchese G. Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. Maturitas 53:77-82, 2006.
25. Lippert TH, Seeger H, Mueck A. Clinical and pharmacological characteristics of the conjugated equine estrogens. Is their use in postmenopausal hormone replacement therapy still up to date? Arnzneimitteltherapie 17:362-4, 1999.
26. O 'C onnell MB. Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol 35(Suppl):18-24S, 1995.
27. Bhavanani BR. Pharmacokinetics and pharmacodynamics of con- jugated equine estrogens: chemistry and metabolism. Proc Soc Exp Biol Med 217:6-16, 1998.
28. Lippert TH, Seeger H, Mueck A. Pharmocodynamics and toxi- cology of different estrogens. Hormone replacement in post- menopausal women: are all estrogens equal? Gynecol Endocrinol 15:26-33, 2001.
29. Ayres S, Abplanalp W, Liu J, Ravi T. Mechanisms involved in the protective effect of estradiol-17beta on lipid peroxidation and DNA damage. Am J Physiol 274:E1002-8, 1997.
30. Subbiah MT, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Antioxidant potential of speciffic estrogens on lipid peroxidation. J Clin Endocrinol Metab 77:1095-7, 1993.
31. Taniguchi S, Yanase T, Kobayashi K, et al. Catechol estrogens are more potent antioxidants than estrogens for the Cu(2) catalyzed oxidation of low or high density lipoprotein: anti- oxidative effects of steroids on lipoproteins. Endocr J 41:605-11, 1994.
32. Ke R, Todd D, Ahokas R. Effect of short-term hormone therapy on oxidative stress and endothelial function in African American and Caucasian postmenopausal women. Fertil Steril 79:1118-22, 2003.
33. Bednarek-Tupikowska G, Tupikowski K, Bidzinska B, et al. Serum lipid peroxides and total antioxidant status in postmenopausal women on hormone replacement therapy. Gynecol Endocinol 19:57-63, 2004.
34. Halliwell B, Grootveld M. The measurement of free radical reac- tions in humans. Some thoughts for future experimentation. FEBS Lett 213:9-14, 1987.
35. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Molec Biol 108:101-6, 1998.
36. Armstrong D, Browne R. The analysis of free radicals, lipid per- oxides, antioxidant enzymes and compounds to oxidative stress as applied to the clinical chemistry laboratory. Adv Exp Med Biol 366:43-58, 1994.
37. Stadtman ER, Oliver CN. Metal-catalyzed oxidation of proteins. Physiological consequences. J Biol Chem 266:2005-8, 1991.
38. Kampa M, Nistikaki A, Tsaousis V. A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Clin Pathol 2:3-18, 2002.
39. Beckman KB, Arnes B. Oxidative decay of DNA. J Biol Chem 272:19633-6, 1997.
40. Espeland M, Hogan P, Fineberg S, et al. Effects of postmenopausal therapy on glucose and insulin concentration. Diabetes Care 21:189-95, 1998.
41. Kanaya A, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 138:1-9, 2003.
42. Liu S, Le May C, Wong MP, et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 58:2292-302, 2009.
43. Friday K, Dong C, Fontenot R. Conjugated equine estrogen improves glycemic control and blood lipoproteins in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 86:48-52, 2001.
44. Lamon-Fava S, Herrington DM, Horvath KV, Schaefer EJ, Asztalos BF. Effect of hormone replacement therapy on plasma lipoprotein levels and coronary atherosclerosis progression in postmenopausal women according to type 2 diabetes mellitus status. Metabolism 59:1794-800, 2010.
45. Lamon-Fava S, Herrington DM, Reboussin DM, et al. Changes in remnant and high-density lipoproteins associated with hormone therapy and progression of coronary artery disease in postmenopausal women. Atherosclerosis 205:325-30, 2009.
46. Lamon-Fava S, Posfai B, Asztalos BF, Horvath KV, Dallal GE, Schaefer E. Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high- density lipoproteins. Metabolism 52:1330-6, 2003.
47. Arteaga E, Rojas A, Villaseca P, Bianchi M, Arteaga A, Duran D. In vitro effect of estradiol, progesterone, testosterone and of combined estradiol/progestins on low density lipoprotein oxidation in postmenopausal women. Menopause 5:16-23, 1998.
48. Ozden S, Dildar K, Hakan Y, Guilzar K. The effects of hormone replacement therapy on lipid peroxidation and antioxidant status. Maturitas 38:165-70, 2001.
49. Wen Y, Doyle M, Norris L, et al. Combined oestrogen-progesterone replacement therapy does not inhibit low-density lipoprotein oxidation in postmenopausal women. Br J Clin Pharmacol 47:315-21, 1999.
50. Naziroglu M, Simsek M, Simsek H, Aydilek N, Ozcan Z, Artilgan R. The effects of hormone replacement therapy combined with vitamins C and E on antioxidant levels and lipid profiles in postmenopausal women with type 2 diabetes. Clin Chim Acta 344:63-71, 2004.
51. Wassmann K, Wassmann S, Nickenig G. Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function. Circ Res 97:1046-54, 2005.
52. Demirbag R, Yilmaz R, Erel O. The association of total antioxidant capacity with sex hormones. Scand Cardiovasc J 36:172-6, 2005.